

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
WOCKHARDT BIO AG,
TEVA PHARMACEUTICALS USA, INC.,
AUROBINDO PHARMA U.S.A., INC.,
Petitioners,

v.

ASTRAZENECA AB,
Patent Owner.

Case: IPR2015-01340¹
U.S. Patent No. RE44,186

PATENT OWNER ASTRAZENECA AB'S EXHIBIT LIST
(as of November 18, 2016)

¹ Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-01122, and Petitioner Aurobindo from IPR2016-01117 have been added as Petitioners to this proceeding.

Exhibit	Description	Status
Exhibit 2001	Doreen M. Ashworth et al., <i>4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV</i> , 6 BIOORG. & MED. CHEM. LETT. 2745 (1996)	Served and Filed
Exhibit 2002	David R. Magnin et al., <i>Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-L-cis-4,5- methanoproline nitrile-Based Inhibitors</i> , 47 J. MED. CHEM. 2587 (2004)	Served and Filed
Exhibit 2003	Jeffrey A. Robl & Lawrence G. Hamann, <i>The Discovery of the Dipeptidyl Peptidase-4 (DPP4) Inhibitor Onglyza™: From Concept to Market</i> , in ACCOUNTS IN DRUG DISCOVERY: CASE STUDIES IN MEDICINAL CHEMISTRY (Joel C. Barrish et al. eds., 2011)	Served and Filed
Exhibit 2004	AstraZeneca Annual Report and Form 20-F Information 2014, available at www.astrazeneca.com/annualreport2014	Served and Filed
Exhibit 2005	Jens J. Holst & Carolyn F. Deacon, <i>Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes</i> , 47 DIABETES 1663 (1998)	Served and Filed
Exhibit 2006	Kathleen Aertgeerts et al., <i>Crystal Structure of Human Dipeptidyl Peptidase IV in Complex with a Decapeptide Reveals Details on Substrate Specificity and Tetrahedral intermediate Formation</i> , 13 PROTEIN SCI. 412 (2004)	Served and Filed

Exhibit	Description	Status
Exhibit 2007	K. Augustyns et al., <i>The Unique Properties of Dipeptidyl- Peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV Inhibitors</i> , 6 CURR. MED. CHEM. 311 (1999)	Served and Filed
Exhibit 2008	George R. Flentke et al., <i>Inhibition of Dipeptidyl Aminopeptidase IV (DP-IV) by Xaa-boroProdipeptides and Use of These Inhibitors to Examine the Role of DP-IV in T-cell Function</i> , 88 PROC. NAT'L ACAD. SCI. 1556 (1991)	Served and Filed
Exhibit 2009	Robert P. Pauly et al., <i>Improved Glucose Tolerance in Rats Treated With the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide</i> , 48 METAB. 385 (1999)	Served and Filed
Exhibit 2010	Hans-U Demuth et al., Abstract, <i>Single Dose Treatment of Diabetic Patients by the DP IV Inhibitor P32/98</i> , 49 DIABETES 413-P (2000)	Served and Filed
Exhibit 2011	U.S. Patent No. 5,939,560	Served and Filed
Exhibit 2012	Paul Rothenberg et al., Abstract, <i>Treatment with a DPP-IV Inhibitor, NVP-DPP728, Increases Prandial Intact GLP-1 Levels and Reduced Glucose Exposure in Humans</i> , 49 DIABETES 160-OR (2000)	Served and Filed
Exhibit 2013	U.S. Patent No. 6,166,063	Served and Filed
Exhibit 2014	Ligaya M. Simpkins et al., <i>Potent Non-Nitrile Dipeptidic Dipeptidyl Peptidase IV Inhibitors</i> , 17 BIOORG. & MED. CHEM. LETT. 6476 (2007)	Served and Filed

Exhibit	Description	Status
Exhibit 2015	János Fischer et al., <i>Pioneer and Analogue Drugs, in ANALOGUE-BASED DRUG DISCOVERY III 3</i> (János Fischer et al. eds., 2013)	Served and Filed
Exhibit 2016	Thomas E. Hughes et al., <i>NVP-DPP728: (1-[[[2-[(5- Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine)</i> , a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV, 38 <i>BIOCHEM.</i> 11597 (1999)	Served and Filed
Exhibit 2017	Coralie Nguyen et al., <i>Specific and Irreversible Cyclopeptide Inhibitors of Dipeptidyl Peptidase IV Activity of the T-Cell Activation Antigen CD26</i> , 41 <i>J. MED. CHEM.</i> 2100 (1998)	Served and Filed
Exhibit 2018	Aiyang Wang et al., <i>Potency, Selectivity and Prolonged Binding of Saxagliptin to DPP4: Maintenance of DPP4 Inhibition by Saxagliptin In Vitro and Ex Vivo When Compared to a Rapidly- Dissociating DPP4 Inhibitor</i> , 12 <i>BMC PHARM.</i> 1 (2012)	Served and Filed
Exhibit 2019	Defendants Joint Initial Invalidation Contentions Regarding U.S. Patent No. RE44,186	Served and Filed
Exhibit 2020	M.A. Nauck et al., <i>Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with NIDDM</i> , 39 <i>DIABETOLOGIA</i> 1546 (1996)	Served and Filed
Exhibit 2021	Nancy L. Thompson et al., <i>A Fischer Rat Substrain Deficient in Dipeptidyl Peptidase IV Activity Makes Normal Steady-State RNA Levels and an Altered Protein: Use as a Liver-Cell Transplantation Model</i> , 273 <i>J. BIOCHEM.</i> 497 (1991)	Served and Filed

Exhibit	Description	Status
Exhibit 2022	Int'l Pub. No. WO 95/15309	Served and Filed
Exhibit 2023	U.S. Patent No. 6,011,155	Served and Filed
Exhibit 2024	Von R. Hiltmann et al., <i>2-Acylaminopyridin-Derivate mit morphinagonistischer und - antagonistischer Wirksamkeit</i> , 24 ARZNEIM. FORSCH. 584 (1974)	Served and Filed
Exhibit 2025	U.S. Patent No. 4,591,598	Served and Filed
Exhibit 2026	German Patent Pub. No. 25 21 895 A1	Served and Filed
Exhibit 2027	U.S. Patent No. 3,325,478	Served and Filed
Exhibit 2028	Stephen Hanessian et al., <i>Probing the Importance of Spacial and Conformational Domains in Captopril Analogs for Angiotensin Converting Enzyme Activity</i> , 8 BIOORG. & MED. CHEM. LETT. 2123 (1998)	Served and Filed
Exhibit 2029	Koert Gerzon et al., <i>The Adamantyl Group in Medicinal Agents I. Hypoglycemic N-Arylsulfonyl-N'adamantylureas</i> , 6 J. MED. CHEM. 760 (1963)	Served and Filed
Exhibit 2030	F. R. Rubio et al., <i>Urinary Metabolites of Rimantadine in Humans</i> , 16 DRUG METAB. & DISPOSITION 773 (1988)	Served and Filed

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.